The ❓ at ODAC matters! (shout out to recent @WolverHeme pod ep discussing the recent STARGLO and AQUILA- based decisions).. if the ❓ is about the “favorability of the proposed dosage”, makes sense that it’s going to be a no… but it still should be an option for patients IMO
ODAC voted against the favorability of belantamab mafodotin in combination with dexamethasone and pomalidomide or bortezomib in multiple myeloma. #mmsm | @FDAOncology @US_FDAView quoted post on X
cancernetwork.com/view/odac-vote…